New trends on obesity and NAFLD in Asia DOI Open Access

Jian-Gao Fan,

Seung Up Kim, Vincent Wai–Sun Wong

и другие.

Journal of Hepatology, Год журнала: 2017, Номер 67(4), С. 862 - 873

Опубликована: Июнь 20, 2017

Язык: Английский

From NASH to HCC: current concepts and future challenges DOI
Quentin M. Anstee, Helen L. Reeves, Elena Kotsiliti

и другие.

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2019, Номер 16(7), С. 411 - 428

Опубликована: Апрель 26, 2019

Язык: Английский

Процитировано

1159

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study DOI Creative Commons
Joong‐Won Park, Minshan Chen,

M. Colombo

и другие.

Liver International, Год журнала: 2015, Номер 35(9), С. 2155 - 2166

Опубликована: Март 5, 2015

Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort undertaken to improve understanding real-life management patients with HCC, from diagnosis death.Data were collected retrospectively January 2005 September 2012 by chart reviews eligible newly diagnosed at participating institutions.Forty-two sites in 14 countries contributed final data for 18 031 patients. Asia accounted 67% patients, Europe 20% and North America 13%. As expected, risk factor hepatitis C virus America, Japan, B China, South Korea Taiwan. Barcelona Clinic Liver Cancer stage Europe, China Korea, A Taiwan Japan. Across all stages, first treatment frequently transarterial chemoembolization percutaneous ethanol injection or radiofrequency ablation Japan resection Survival varied significantly region, median overall survival not reached 60, 33, 31, 24 23 months respectively (P < 0.0001).Initial results confirm previously reported regional trends patient demographic characteristics factors, document heterogeneity approaches across regions/countries underscore need earlier

Язык: Английский

Процитировано

1017

Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis DOI Creative Commons
Daniela Sia, Augusto Villanueva, Scott L. Friedman

и другие.

Gastroenterology, Год журнала: 2016, Номер 152(4), С. 745 - 761

Опубликована: Дек. 30, 2016

Язык: Английский

Процитировано

1017

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial DOI
Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro

и другие.

The Lancet Oncology, Год журнала: 2015, Номер 16(13), С. 1344 - 1354

Опубликована: Сен. 8, 2015

Язык: Английский

Процитировано

992

New trends on obesity and NAFLD in Asia DOI Open Access

Jian-Gao Fan,

Seung Up Kim, Vincent Wai–Sun Wong

и другие.

Journal of Hepatology, Год журнала: 2017, Номер 67(4), С. 862 - 873

Опубликована: Июнь 20, 2017

Язык: Английский

Процитировано

986